Loading…
Alan Health Technologies Inc. was cited for misbranding compounded semaglutide and tirzepatide drug products by falsely representing that Alan was the compounder when it was not, violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The company's website displayed product labels identifying "Alan" as the manufacturer, creating misleading claims about the source and identity of these compounded drugs. These false or misleading representations resulted in misbranded products being introduced into interstate commerce in violation of section 301(a) of the FDCA.